Podcasts about sglt2

SGLT2 inhibitors in CKD: are they really effective in all patients?

If you enjoy a blend of online learning and podcast-style listening that you can fit into your busy life, then this podcourse is for you. Listen to this 3-part audio series, then go to MIMSLearning.co.uk to read the downloadable worksheets and complete the multiple-choice quizzes, to get up to speed with all the key points primary care professionals need to know about chronic kidney disease (CKD). In this episode (part 2), consultant nephrologist Dr Andrew Frankel covers monitoring and management of CKD. He explains why lifestyle modifications are ‘the foundation' for improving CKD outcomes, gives an update on best practice for medicine optimisation and advises on how frequently patients should be followed up.MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser. Educational objectivesAfter listening to this podcourse episode, healthcare professionals should be better able to:Understand the role of lifestyle changes in CKD management Recall the benefits of SGLT2 inhibitors in CKD patients Apply the ‘3 in 3' medication optimisation strategy Recognise the impact of CKD impact on cardiovascular risk Explain how frequently patients with CKD should be followed up Consider how systematic CKD patient identification and coding could be implemented MIMS LearningSubscribe to MIMS LearningCKD podcourse with Dr Andrew Frankel, part 3: advanced managementCKD podcourse with Dr Andrew Frankel, part 1: diagnosis and classificationManaging patients with combined heart and kidney diseaseGuidance update: NICE guidelines on chronic kidney diseaseDiabetes-related kidney disease: prevalence, diagnosis, and impactPodcast: diagnosis and management of diabetes-related kidney diseaseCKD: the hidden public health emergency Hosted on Acast. See acast.com/privacy for more information.

Enquanto o diabetes tipo 2 avançou com múltiplas opções terapêuticas, o que realmente temos hoje para o paciente com DM1 que desenvolve albuminúria ou queda da TFG?Neste episódio do podcast Nefropapers, a Dra. Maria Amélia traz o que já está bem estabelecido, o que ainda é off-label e quais são as perspectivas reais para o futuro.Você vai entender:⦁ Qual é o risco real de doença renal no diabetes tipo 1⦁ Quais fatores aceleram progressão da doença⦁ Quando IECA ou BRA estão indicados, mesmo sem hipertensão⦁ Por que SGLT2 não é recomendado oficialmente no DM1⦁ O que esperar de finerenona e análogos de GLP-1 nessa população--------------------------------------------Venha fazer parte da maior comunidade de Nefrologia:

Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?⁠Cuidados com doença aguda (sick day) e hipovolemia⁠Cuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P,  et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho,  Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...

Coming to you from the #NCPA2025 expo floor, host John Beckner and co-host Ed Cohen talk with Brian Connelly, president and CEO of TheracosBio, about Brenzavvy (bexagliflozin), an FDA-approved oral SGLT2 inhibitor for adults with Type 2 diabetes. They discuss how the company's model bypasses PBMs to offer pharmacists and patients a fair, transparent price.

In this episode of Clinical Conversations, Dr Marilena Giannoudi discusses cardiorenal metabolic disease with Dr Andrew Frankel. Their discussion provides an overview of this common cause of chronic kidney disease (CKD) and they focus on the management of cardiorenal metabolic disease, with Dr Frankel highlighting the importance of lifestyle management and patient education and engagement, and the pharmacotherapy 'four pillars' of RAAS inhibition, SGLT2 inhibition, blood pressure control, and MR antagonism. Explore this and more in this episode. Dr Andrew Frankel has been working as a consultant nephrologist at Imperial College Healthcare NHS trust since 1995 and works at the Imperial Renal and Transplant Centre, which is one of the largest kidney units in Europe catering for a population base of over three million. He has experience in managing all aspects of kidney disease but has a particular interest in relation to the management of kidney disease in the context of diabetes, cardiac disease and obesity. Dr Marilena Giannoudi is a cardiology registrar based in Leeds. She is Co-Chair of RCPE's Trainees and Members' Committee. -- Links -- NICE Guideline (NG203) - Chronic kidney disease: assessment and management https://www.nice.org.uk/guidance/ng203 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/CVD-and-Diabetes-Guidelines For Kidneys Sake Podcast - By Dr Andrew Frankel and colleagues https://www.forkidneyssake.com/ Recording date: 24 November 2025 -- Follow us -- https://www.instagram.com/rcpedintrainees https://x.com/RCPEdinTrainees -- Upcoming RCPE events -- https://www.rcpe.ac.uk/events -- Become an RCPE Member -- https://www.rcpe.ac.uk/membership/join-college Feedback: cme@rcpe.ac.uk This podcast is from the Trainees & Members' Committee (T&MC) of the Royal College of Physicians of Edinburgh (RCPE).

In Deutschland leben etwa 9 Millionen Menschen mit einem diagnostizierten Typ-2-Diabetes. Jedes Jahr kommen ca. 450.000 Patientinnen und Patienten neu dazu: Die Belastung des Gesundheitssystems wird aller Voraussicht nach in den kommenden Jahren zunehmen. Bei vielen Betroffenen mit Diabetes mellitus treten zeitgleich Komorbiditäten auf, darunter oft kardiovaskuläre Erkrankungen bzw. chronische Nierenkrankheit. Man spricht auch vom kardiorenal-metabolischen Syndrom.

Dra. Maria Estela e Dr. Gabriel Montezuma trazem mais destaques do Congresso Americano com os cinco estudos que mais chamaram atenção e, principalmente, o que eles mudam na prática clínica:1. FINE-ONE: finerenona em diabetes tipo 1 com DRC e o impacto na albuminúria.2. MIRO CKD: combinação de antagonista de mineralocorticoide não esteroidal com SGLT2 em DRC, incluindo pacientes não diabéticos.3. Creatinina x Cistatina C: quando o “gap” entre os dois muda desfecho cardiovascular e renal.4. LIBERATE-D: estratégia mais conservadora de diálise na IRA pode melhorar recuperação?5. PISCES: suplementação de ômega 3 em hemodiálise e redução de eventos cardiovasculares.

Join me for a fascinating deep dive into the science of immune aging with Dr. Natalia Mitin, founder and CEO of Sapere Bio. We explore why the aging of the immune system is the primary driver of aging for the entire body and unpack the concept of cellular senescence—often called "zombie cells"—where stressed cells persist and create chronic inflammation. Dr. Mitin explains why consumer tests that assign a specific "biological age" in years are often scientifically lacking compared to measuring where you stand within a population's trajectory. We also discuss cutting-edge longevity targets, including T-cell exhaustion (and how drugs like Rapamycin and SGLT2 inhibitors address it), the critical role of gut health (where 70% of the immune system resides), and how mitochondrial function in stem cells can correlate with an extra 15 years of healthspan.

N478 - EASD 2025 - Diabetes Tipo 2: GLP-1 e SGLT2 se destacam após Metformina - André Vianna, Fernando Valente e Melanie Rodacki by SBD

N413 - ADA 2025 - GLP-1, GIP-GLP-1 ou SGLT2: qual usar? - Rodrigo Lamounier e Márcio Krakauer by SBD

N457 - ADA 2025 - GLP-1 e SGLT2 em transplantados renais! - Marcio Krakauer e Talita Trevisan by SBD

N411 - ADA 2025 - Alzheimer e Diabetes: GLP-1 reduz risco em 68% e SGLT2 em 25%! - Fernando Valente, João Salles e Ruy Lyra by SBD

N448 - ADA 2025 - SGLT2 e GLP-1 no Tipo 1: Novos dados e cuidados! - Marcio Krakauer e Rodrigo Lamounier by SBD

N433 - ADA 2025 - SGLT2 para todos? Quem precisa não está usando! - Fernando Valente e Virgínia Fernandes by SBD

  Chronic kidney disease now affects nearly 850 million people worldwide, yet early detection and simple, evidence-based interventions can dramatically change the trajectory of both kidney and cardiovascular health.

SGLT2 inhibitors have a multitude of beneficial effects on horses with equine metabolic syndrome.Read the full article at https://equimanagement.com/research-medical/research/updates-on-sglt2-inhibitors-for-horses/. Mentioned in this episode:EquiManagement on Audio All the articles you have come to love in EquiManagement Magazine are now available in this podcast for free. Each article is released as its own separate episode to make them quick and easy to listen to. EquiManagement always has the latest insights on equine health, veterinary practice management, and veterinarian wellness.

Updates on SGLT2 inhibitors, fish oil and hemodialysis, GLP-1 drugs, and more: Katherine R. Tuttle, MD, education committee co-chair of Kidney Week 2025 and a professor of medicine at the University of Washington, shares clinical research highlights from the recent meeting. Related Content: SGLT2 Inhibitors, Fish Oil in Hemodialysis, GLP-1 Drugs, and More—Highlights From Kidney Week

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: This episode was supported by Greater Manchester NHS who received support from Boehringer.  You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

In this in-depth conversation, Dr. Brad Stanfield sits down with Dr Matt Kaeberlein to discuss his journey from a primary care physician in New Zealand to a leading voice in the evidence-based longevity space. We cover the launch and philosophy behind his YouTube channel, the challenges and exciting results of his self-funded rapamycin clinical trial, and his critical perspective on supplements, medical guidelines, and the future of aging research.Dr. Stanfield provides a unique clinician's viewpoint on hot topics like GLP-1 agonists (Ozempic), SGLT2 inhibitors, vitamin D testing, and the pitfalls of biological age clocks. We also dive into a spirited debate on the role of medical societies, the balance between risk and benefit in prescribing medications, and why he believes the field of longevity is still in its early stages of discovery.Key Topics & Timestamps:00:00 - Introduction00:52 - Brad's Background02:47 - Starting the YouTube Channel & Philosophy on Science Communication07:39 - The Rigor of Clinical Data vs. Misinformation10:14 - Admitting Mistakes in Public (Resveratrol, Metformin)14:40 - Funding and Designing the Rapamycin Clinical Trial19:25 - Rapamycin Trial Results Submitted & Plans for a PhD23:28 - Preventative Care: New Zealand vs. US Healthcare Systems27:59 - The Vitamin D Debate: To Test or Not to Test?35:18 - Trust in Medical Guidelines & The Hormone Replacement Therapy Controversy43:42 - The Problem with Biological Age Clocks46:22 - Patient-Centered Care: Inform vs. Decide in Medicine49:49 - How to Judge the Quality of a Clinical Trial (CONSORT)53:44 - Risk vs. Benefit: When Should We Prescribe Preventative Drugs?58:05 - GLP-1 Agonists (Ozempic) and SGLT2 Inhibitors in Practice01:02:00 - Brad's Personal Use of an SGLT2 Inhibitor01:05:38 - The State of Longevity Research: How Much Do We Really Know?01:08:34 - Closing RemarksDISCLAIMER: The information provided on the Optispan podcast is intended solely for general educational purposes and is not meant to be, nor should it be construed as, personalized medical advice. No doctor-patient relationship is established by your use of this channel. The information and materials presented are for informational purposes only and are not a substitute for professional medical advice, diagnosis, or treatment. We strongly advise that you consult with a licensed healthcare professional for all matters concerning your health, especially before undertaking any changes based on content provided by this channel. The hosts and guests on this channel are not liable for any direct, indirect, or other damages or adverse effects that may arise from the application of the information discussed. Medical knowledge is constantly evolving; therefore, the information provided should be verified against current medical standards and practices.Dr. Brad Stanfield's Socials:Website: https://drstanfield.com/YouTube: https://www.youtube.com/@DrBradStanfieldX: https://x.com/BradStanfieldMDMore places to find us:Twitter: https://x.com/Optispan_IncTwitter: https://x.com/mkaeberlein Linkedin: https://www.linkedin.com/company/optispan/Instagram: https://www.instagram.com/optispan_/  TikTok: https://www.tiktok.com/@optispanhttps://www.optispan.life/

Email List: ⁠https://huntershealthhacks.beehiiv.com/⁠Get My Book On Amazon: ⁠⁠https://a.co/d/avbaV48Download⁠⁠The Peptide Cheat Sheet: ⁠⁠https://peptidecheatsheet.carrd.co/⁠⁠Download The Bioregulator Cheat Sheet: ⁠⁠https://bioregulatorcheatsheet.carrd.co/⁠⁠1 On 1 Coaching Application: ⁠⁠https://hunterwilliamscoaching.carrd.co/⁠⁠Book A Call With Me: ⁠⁠https://hunterwilliamscall.carrd.co/⁠⁠Supplement Sources: ⁠⁠https://hunterwilliamssupplements.carrd.co/⁠⁠Amazon Storefront: ⁠⁠https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY⁠⁠Socials:Instagram: ⁠⁠https://www.instagram.com/hunterwilliamscoaching/⁠⁠Video Topic Request: ⁠⁠https://hunterwilliamsvideotopic.carrd.co/In this episode, I dive deep into what I believe could be the most powerful synergy in the entire world of longevity and metabolic optimization — the combination of SGLT2 inhibitors (like Jardiance and Farxiga) with GLP-1 agonists (like Retatrutide, Tirzepatide, and Semaglutide).These medications were originally created for diabetics, but what we're learning now is that they may be rewriting the entire playbook on healthspan and lifespan extension. I break down the research showing how SGLT2 inhibitors not only lower blood glucose but also improve cardiovascular health, protect the kidneys, reduce inflammation, and even clear senescent cells — all while mimicking the effects of caloric restriction and fasting.Then, I explain how pairing them with a GLP-1 creates a metabolic symphony unlike anything else we've ever seen. Together, they reduce insulin resistance, improve energy metabolism, and activate the same longevity pathways linked to caloric restriction, AMPK activation, and mitochondrial renewal.If you care about living longer, staying leaner, and protecting every organ system in your body, this episode is a must-listen. I share what I've seen personally, what's happening in clinical data, and why I believe the GLP-1 + SGLT2 combo could end up being one of the greatest discoveries in modern medicine for both health and performance.

CME credits: 0.50 Valid until: 05-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-hidden-threat-transforming-ckd-care-across-the-diabetes-spectrum/36523/ Chronic kidney disease (CKD) is a common complication in type 2 diabetes that is closely linked to cardiovascular risk and often diagnosed late. Early detection with UACR and eGFR, plus treatment with therapies such as SGLT2 inhibitors, finerenone, and GLP-1 receptor agonists, has transformed treatment and guideline recommendations. Attention is now shifting to CKD in type 1 diabetes. Ongoing trials, such as FINE-ONE with finerenone, may soon expand therapeutic options and ensure no patient is left behind. =

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter revisits the “proven, promising, fuzzy, noise, nonsense” scale and applies it to a variety of popular topics. He begins with a refresher on what each category represents before classifying a range of interventions based on the strength of their supporting evidence. The conversation spans three main areas: drugs for geroprotection (including GLP-1 receptor agonists, SGLT2 inhibitors, methylene blue, and telomere-lengthening supplements), the use of low-dose aspirin for cardiovascular disease prevention, and strategies to improve muscle mass through optimal protein intake and follistatin gene therapy. This episode provides a clear, evidence-based overview for listeners seeking to understand where these popular health and longevity interventions stand on the spectrum of scientific credibility. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the AMA #76 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: A scale for evaluating scientific claims: proven, promising, fuzzy, noise, or nonsense [1:30]; Strong convictions, loosely held: the mindset that separates great scientists from the rest [7:30]; GLP-1 receptor agonists: are there benefits beyond improving metabolic health and promoting weight loss? [12:45]; GLP-1 drugs and the brain: exploring the potential cognitive benefits [18:45]; GLP-1 drugs and lifespan: examining the evidence for potential geroprotective effects [23:00]; Rapamycin and geroprotection: why it remains in the “promising” category [25:45]; SGLT2 inhibitors and their potential geroprotective effect [27:30]; Methylene blue: examining the evidence of an anti-aging effect [34:45]; Methylene blue's potential neuroprotective effects: limited and inconsistent evidence in humans, and the challenges of dosing and safety [41:15]; Telomeres: what they are, how they relate to aging, and why telomere-lengthening supplements lack credible scientific evidence [43:45]; Does the idea of targeting telomere length to extend lifespan have scientific merit? [50:15]; Low-dose aspirin for cardiovascular disease prevention: weighing its clot-prevention benefits against bleeding risks across different populations [55:00]; Rethinking the protein RDA: why most people need twice the recommended amount for muscle health [1:00:45]; Debunking the protein–cancer myth: why higher protein intake doesn't promote tumor growth [1:06:15]; The biology of follistatin and myostatin, and why follistatin gene therapy has become an emerging topic of interest for muscle growth [1:13:15]; Follistatin gene therapy for muscle growth: state of the evidence in animals and humans, and the technical challenges and regulatory barriers [1:17:00]; Why injectable follistatin is theoretically possible but impractical for real-world use [1:23:15]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

In this education program through Vividh Bharati (All India Radio), Dr. Sunil Gupta explained in detail that diabetes is a multifactorial disease that can affect multiple organs including the eyes, nerves, liver, kidneys, heart, and even sexual health. He highlighted that non-alcoholic fatty liver disease (NAFLD), sleep disturbances, frozen shoulder, and sexual dysfunction are among the common complications associated with diabetes.  He elaborated that diabetes medications—such as Metformin, Glitazones, and SGLT2 inhibitors—work in different ways: some drugs like sulfonylureas increase insulin secretion, others improve insulin sensitivity, while some help eliminate excess sugar through urine. Dr. Gupta clarified that starting medication does not necessarily mean lifelong dependency; if blood sugar levels remain under good control, the dosage can be reduced under dose monitoring or, in some cases, the medication can be stopped under medical supervision.  Concluding his address, he emphasized that “the true treatment of diabetes is not just controlling blood sugar but taking care of the whole body through a disciplined and healthy lifestyle.”  Expert- Dr Sunil Gupta  Anchor- Mrs. Shraddha Bharadwaj  Podcast: 22/02/2019  Recorded at: Akashwani Nagpur  Episode: 87

A large real-world study of over 1.2 million adults with type 2 diabetes found that SGLT2 inhibitors and GLP-1 receptor agonists reduced major cardiovascular events compared with metformin, while sulfonylureas and insulin increased risk. A separate French population study showed no association between first-trimester mRNA COVID-19 vaccination and congenital malformations, supporting vaccine safety in pregnancy. Finally, researchers at Mass General Brigham reported that large language models can produce “sycophantic” but incorrect medical advice, emphasizing the need for clinician oversight when using AI in healthcare.

What if your patient's blood sugar looks “okay,” but their kidneys are already under attack?In this episode of ReInvent Healthcare, Dr. Ritamarie uncovers the common progression of kidney damage fueled by insulin resistance and elevated glucose. Most practitioners miss the early clues. And most patients never feel symptoms… until it's too late.Discover the early biochemical markers, the overlooked tests, and the clinical action steps you can take now to prevent progression to fibrosis, dialysis, and even renal failure.What's Inside This Episode?The silent mechanisms linking insulin resistance to kidney scarring and declineWhy normal creatinine and BUN may be misleading and what to test insteadWhich labs signal decline before patients show symptomsThe food patterns and protein levels that support vs. stress the kidneysTargeted botanicals, nutrients, and fasting strategies for protecting kidney functionHow to approach intermittent fasting, inflammation, and oxalates with nuanceWhen medications like SGLT2 inhibitors or ACE inhibitors may be protectiveThe practitioner's role in prevention, education, and root-cause reversalResources and Links:Download our FREE Health Detective Checklist.Download our FREE Guide to for Lab Test RecommendationsJoin the Next-Level Health Practitioner Facebook group here for free resources and community supportReserve your spot for our Reinvent Healthcare Online Event Nov 7-9! It's the event of the year for practitioners serious about root-cause healing. Visit INEMethod.com for advanced health practitioner training and tools to elevate your clinical skills and grow your practice by getting life-changing results. Check out other podcast episodes here

In this VETgirl veterinary continuing education podcast, we interview Dr. Christopher G. Byers, DACVIM, DACVECC about SGLT2 inhibitors for the treatment of diabetes mellitus to manage hyperglycemia in cats. Tune in to know how to select the ideal feline diabetic candidate for this diabetes mellitus treatment option!Sponsored By: Boehringer Ingelheim

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.

Heart failure remains a leading cause of hospitalization, prompting ongoing research into treatment strategies that improve outcomes for patients. A recent study explores the potential of combining an MRA agent and SGLT2 inhibitor, showing meaningful clinical benefit while also reinforcing the need for thoughtful patient selection and safety monitoring. Tune in to explore how this evidence may shape pharmacist-driven care and contribute to more confident, individualized treatment decisions.HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTZachary Cox, PharmDProfessorLipscomb University College of PharmacyJoshua Davis Kinsey has no relevant financial relationships to disclose. Zachary Cox is a consultant for Roche, Reprieve Cardiovascular, Abiomed, Vectorious, Kestra Medical Technologies, and WhiteSwell. He was also a consultant for Lexicon Pharmaceuticals (ended 2025) and conducted research for AstraZeneca (ended 2024). All relevant financial relationships have been mitigated.  Pharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe the clinical evidence supporting the use of multiple drug classes in combination therapy for heart failure.2. Identify pharmacist considerations for evaluating patient-specific factors related to efficacy and safety of combination treatment approaches.0.05 CEU/0.5 HrUAN: 0107-0000-25-299-H01-PInitial release date: 10/20/2025Expiration date: 10/20/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

A new meta-analysis in HeartRhythm found that SGLT2 inhibitors reduced sudden cardiac death risk by about 18% across patients with type 2 diabetes, heart failure, or chronic kidney disease, with consistent effects and minimal trial variation. A Cochrane review of over 100,000 participants showed RSV vaccines are highly effective and safe: protein-based shots cut severe lower respiratory infections in older adults by ~75% and protected infants when given to pregnant mothers, halving RSV-related care and hospitalizations. Finally, WHO and EMA reaffirmed acetaminophen's safety in pregnancy, rejecting suggested links to autism or neurodevelopmental harm, noting decades of safe use and the risks of untreated pain or fever.

How do you take one complex medical concept and make it clear, accurate, and actionable for both clinicians and patients, without losing credibility?If you're a CME writer, you know the challenge of translating science into education that actually sticks. But as more CME projects tether clinician education with patient-facing components, the real test is flexing your craft to serve two very different audiences at once. Get this right, and you not only improve learning, you expand your professional scope and impact.In this episode, you'll discover:How to apply practical frameworks to dual-audience writing.Structural techniques that make content engaging, empathetic, and accessible.A simple 3-sentence exercise to sharpen clarity for patients and precision for clinicians—anytime, anywhere.

In this Healthed lecture, Dr Ted Wu explores the impact of cardiovascular outcomes trials in patients with type 2 diabetes, which have led to significant advances in cardioprotective therapies. As a result of these trials, medications such as SGLT2 inhibitors and GLP1 receptor agonists are now recommended as first-line treatments for individuals with, or at risk of, cardiovascular disease. Dr Wu addresses the pressing question of what comes next in this evolving field. This lecture focuses on the opportunities and challenges that future research is likely to face as it continues to investigate cardiovascular outcomes in patients living with type 2 diabetes.See omnystudio.com/listener for privacy information.

CME credits: 0.25 Valid until: 01-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-outcomes-evidence-based-strategies-for-treating-patients-with-heart-failure-with-mildly-reduced-or-preserved-left-ventricular-ejection-fraction/29905/ Join Drs. Scott Solomon and John McMurray as they examine the new indication for finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in treating patients with heart failure with LVEF ≥40%. Drawing on data from the FINEARTS-HF trial, faculty discuss patient selection, dosing considerations based on renal function, and the additive benefits of combining finerenone with SGLT2 inhibitors. A clinical case illustrates typical comorbidities—atrial fibrillation, hypertension, and diabetes—and how finerenone may address multiple cardiovascular and metabolic risks. =

Type 2 diabetes is one of the most common chronic conditions in the U.S., but it doesn't have to define or limit your life. In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus—two endocrinologists with decades of experience—break down practical strategies for living well with type 2. From the latest medications and tools to everyday lifestyle choices, they highlight what really makes a difference in the long run. Their goal? To show you that type 2 diabetes is not only manageable but that taking control can actually improve your health and quality of life.Get Educated About What's Happening in Your Body: Understanding insulin resistance, metabolic syndrome, and why type 2 diabetes is more than just “high blood sugar.”Know Your Numbers: The key benchmarks for A1c, blood sugar, cholesterol, and blood pressure—and why even small improvements matter.Build the Right Care Team: How to find and work with providers who can guide you through treatment options and keep you on track.Food and Drink That Work for You: Why portion control, balance, and smart substitutions matter more than strict diets or deprivation.Move Your Body (Without Overthinking Exercise): How realistic activity goals—walking, stretching, or even gardening—can improve insulin sensitivity and overall health.The Medications Changing the Game: Why GLP-1s, SGLT2 inhibitors, and CGMs are considered life-changing tools in type 2 diabetes care—and what you should know about them.And That's Just the Start…: From mental health to long-term complication prevention, there are even more strategies in this episode to help you thrive with type 2 diabetes. ★ Support this podcast ★

In this episode, we give a wrap-up of late-breaking clinical science presented at the ESC Congress 2025 in Madrid. First, David Berg presents the DAPA ACT HF-TIMI 68 trial, reporting on dapagliflozin in patients hospitalized for acute heart failure, along with a meta-analysis of SGLT2 inhibitors in this setting. Next, Javed Butler highlights results of the VICTOR trial, a large phase 3 study of vericiguat in chronic heart failure with reduced ejection fraction. Then, Andre Zimerman discusses the PhysioSync-HF trial, comparing conduction system pacing with biventricular resynchronization therapy in patients with HFrEF. Finally, Kieran Docherty shares insights from a community-based study on the benefits of early initiation of disease-modifying therapy in suspected heart failure.   Additional information: Topic 1: With Gregorio Tersalvi, Mayo Clinic, Rochester, MN - USA, David Berg, Brigham and Women's Hospital, Boston - USA and Novi Yanti Sari, Siloam Hospitals Group, Jakarta - Indonesia Results paper: Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure Replay ESC Congress Hot Line: https://esc365.escardio.org/presentation/312142 Circulation. 2025 Aug 29. doi: 10.1161/CIRCULATIONAHA.125.076575.    Topic 2: With Javed Butler, Baylor Scott & White Health, Dallas - USA and Henrike Arfsten, Medical University of Vienna, Vienna - Austria Results papers: Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial Lancet. 2025 Replay ESC Congress hotline: https://esc365.escardio.org/presentation/312148 doi: 10.1016/S0140-6736(25)01665-4.  Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials Lancet. 2025 Aug 29:S0140-6736(25)01682-4. doi: 10.1016/S0140-6736(25)01682-4.   Topic 3: With Andre Zimerman, Hospital Moinhos De Vento, Porto Alegre - Brazil and Floran Sahiti, University Hospital of Wurzburg, Wurzburg - Germany Methods paper: Conduction system pacing vs biventricular resynchronization in heart failure with reduced ejection fraction and left bundle branch block: Rationale and design of the PhysioSync-HF Trial Am Heart J. 2025 Dec:290:38-45. Replay ESC Congress: https://esc365.escardio.org/session/50327 doi: 10.1016/j.ahj.2025.06.002.   Topic 3: With Kieran Docherty, University of Glasgow, Glasgow - UK and Jolie Bruno, Inserm UMR-S942, Paris - France Results paper: Benefit of early initiation of disease-modifying therapy in community-based patients with suspected heart failure Eur Heart J. 2025 Aug 29:ehaf675. doi: 10.1093/eurheartj/ehaf675.    This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor. 

Disclaimer: The views expressed in this video should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations and circumstances may vary. Sponsored by Abbott Summary In this episode, Dr. Eden Miller discusses the concept of Euglycemic DKA, a condition that can occur even when blood sugar levels are normal. The conversation covers the importance of understanding the symptoms, the role of medications like SGLT2 and GLP1 in increasing the risk of DKA, and the necessity of regular ketone checks. Dr. Miller emphasizes the need for education and empowerment in managing diabetes, especially in unique situations like pregnancy and prolonged fasting. The episode concludes with strategies for preventing Euglycemic DKA. Chapters 00:00 Introduction to Euglycemic DKA 02:00 Understanding Euglycemic DKA 04:08 Impact of Medications on DKA 07:10 Symptoms and Confirmation of DKA 09:20 The Importance of Regular Ketone Checks 11:07 Exploring GLP-1 Medications 12:30 Other Causes of DKA 16:22 Preventing Euglycemic DKA Resources: https://diabetesandobesity-care.com/ https://www.linkedin.com/in/eden-miller-b02a5a178

Here is the second part of my conversation with biochemist Jon Brudvig to delve into the fascinating world of longevity and contemporary health interventions. We tackle topics ranging from SGLT2 inhibitors and their unexpected benefits to the controversial nature of microplastics in our environment. This dialogue is a treasure trove for anyone interested in the intersections of health, science, and longevity. What You'll Learn: Exploring SGLT2 Inhibitors: Discover the multifaceted benefits of SGLT2 inhibitors, originally diabetes drugs, for heart, kidney, and possibly cognitive health. Metformin: A Mixed Bag: Get an overview of the metformin debate, examining its potential benefits and the contentious nature of the research. Fasting Fundamentals: Gain insights into intermittent fasting, its impact on metabolism, potential benefits, and the critical role of resistance training to mitigate muscle loss. Microplastics: An Underestimated Threat: Learn about the insidious presence of microplastics in human tissues and their potential health repercussions. Potential Interventions: Hear about experimental approaches to reducing microplastics in the body, including the potential role of sulforaphane. Key Takeaways: SGLT2 inhibitors: These drugs have shown promising longevity benefits beyond their initial purpose for diabetes management. Metformin's Controversy: While some data suggests potential longevity benefits, criticism exists regarding its exercise interference and study methodologies. The Role of Fasting: Intermittent fasting can be beneficial, particularly for metabolic health, but must be carefully balanced with nutritional needs and physical activity. Microplastics Concern: Ubiquitous in the environment, microplastics are potentially linked to inflammation and adverse health outcomes, necessitating further research and interventions. Self-Experimentation: Personal health experiments, like those done by Jon Brudvig, highlight the importance of understanding one’s own biology in response to health interventions. Resources: Connect with Dr. Jon Brudvig for more insights into longevity and health: LinkedIn: Jon Brudvig Substack: https://jonbrudvig.substack.com/ Support the Podcast: If you found this episode valuable, please consider subscribing to our podcast and leaving a review. Your feedback helps us continue bringing important conversations like these to a wider audience. Whether you're driven by personal health challenges or broader scientific curiosity, this conversation provides a unique peek into the current and future possibilities of living healthier, longer lives. Share this with individuals passionate about health and longevity, and join the ongoing dialogue to advance our understanding and well-being. 00:12 Understanding SGLT2 Inhibitors 02:51 Mendelian Randomization and SGLT2 Inhibitors 06:24 Benefits and Mechanisms of SGLT2 Inhibitors 09:47 Discussion on Metformin 14:36 Intermittent Fasting and Ketone Supplements 17:46 Fasting, Autophagy, and Muscle Health 22:38 Exploring Glycine and N-Acetyl Cysteine 24:48 Microplastics: A Growing Concern 26:25 The Impact of Microplastics on Health 31:54 Self-Experimentation with Sulforaphane 38:33 Final Thoughts and Future Work See omnystudio.com/listener for privacy information.

Diabetic ketoacidosis can be life-threatening but there's some variability in the way it's managed between health settings. Intervention involves intravenous insulin administration, hydration, electrolyte replacement and treatment of the underlying precipitant. In a survey of practitioners from 31 different hospitals in Australia there was an even split between those organisations which followed a fixed rate insulin infusion protocol, usually based on bodyweight, or a variable rate infusion protocol, titrated against blood glucose concentration. Three quarters of survey respondents had worked at another hospital that had different DKA management protocols raising concerns about the cognitive load on junior health staff moving between institutions. In Europe there has been some normalisation towards fixed rate protocols, despite there being no good quality evidence for superiority. In this podcast we hear some theories from two of the authors of the study published recently in the Internal Medicine Journal.12:40 SGLT2 inhbitor-associated ketoacidosis17:26 The cognitive burden of variation across settings25:11 the challenges of researching this questionsGuestsDr Lisa Raven FRACP PhD (St Vincent's Hospital, Sydney)Dr Mahesh Umapathysivam FRACP DPhil (Southern Adelaide Diabetes and Endocrine Service; Royal Adelaide Hospital) Guest HostDr Mervyn Kyi FRACP PhD (Royal Melbourne Hospital; Northern Hospital)ProductionProduced by Dr Mervyn Kyi and Mic Cavazzini DPhil. Music licenced from Epidemic Sound ‘Tree Tops' by Autohacker and ‘Fugent' by Lupus Nocte. Image created and copyrighted by RACP. Editorial feedback kindly provided by RACP physicians Aidan Tan, Hugh Murray, Stephen Bacchi and Aafreen Khalid. Key Reference“Heterogeneity in the management of diabetic ketoacidosis in Australia: a national survey”  [IMJ. 2025]Please visit the Pomegranate Health web page for a transcript and supporting references.Login to MyCPD to record listening and reading as a prefilled learning activity. Subscribe to new episode email alerts or search for ‘Pomegranate Health' in Apple Podcasts, Spotify,Castbox or any podcasting app.

Join Kate, Mark, Gary and Henry as they discuss 4 great new POEMs (studies with the potential to change practice): a digital mental health intervention, the risk of DKA in patients using SGLT2 inhibitors, esketamine's effects on suicidal ideation and unresponsive depression, and whether “one-size-fits-all” thyroid reference ranges misleading.Links:Essential Evidence Plus: www.essentialevidenceplus.comDigital mental health app for depression: https://pubmed.ncbi.nlm.nih.gov/40227715/RIsk of DKA with SGLT2s: pubmed.ncbi.nlm.nih.gov/40070044/Esketamine and resistant depression or suicidality: pubmed.ncbi.nlm.nih.gov/39790081/ What is a normal TSH: https://pubmed.ncbi.nlm.nih.gov/40324200/ Joseph O'Connor and the Escape Line Trilogy (2 great novels): https://www.amazon.com/The-Rome-Escape-Line-Trilogy-2-book-series/dp/B0BSNX3C89 

In this essential episode of Parallax, Dr Ankur Kalra welcomes Dr Shelley Zieroth, Professor of Medicine, clinician-scientist, and advanced heart failure and transplant cardiologist in Winnipeg, Canada. As we mark the 10-year anniversary of the landmark EMPA-REG OUTCOME trial, Dr Zieroth provides a comprehensive update on how SGLT2 inhibitors have revolutionized cardiovascular care. Dr Zieroth takes us through the remarkable journey from the initial 2015 trial that transformed SGLT2 inhibitors from anti-diabetic agents into cardiovascular powerhouses, delivering highly significant reductions in cardiovascular death and heart failure hospitalization. She explores how these medications have become fundamental pillars of cardio-kidney-metabolic medicine, with evidence spanning the entire ejection fraction spectrum. Dr Zieroth discusses prescribing these agents in heart failure - including the straightforward 10-mg daily dosing, monitoring strategies, and crucial patient selection criteria. She shares insights from the recent EMPULSE trial on safe in-hospital initiation, addresses important considerations for diabetic patients, and highlights key contraindications like indwelling catheters that clinicians must recognize. Beyond the basics, Dr Kalra and Dr Zieroth examine the evolving role of SGLT2 inhibitors in valvular disease and diastolic dysfunction, tackle the ongoing reimbursement challenges across different healthcare systems, and discuss the critical importance of multidisciplinary collaboration in the cardio-kidney-metabolic space. They also look ahead to exciting combination therapies on the horizon that promise to further advance heart failure prevention and treatment. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I'm a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients. Doctor Warick Bishop, a cardiologist, author, and keynote speaker, discusses heart failure with preserved ejection fraction (HF PEF) in this podcast episode featuring Dr. Fiona Foo, a cardiologist in the Sydney Cardiology Group. They delve into HF PEF diagnosis, treatment, and prevention strategies, focusing on managing blood pressure, weight, and other risk factors like diabetes and kidney disease. They elaborate on medications such as SGLT2 inhibitors and GLP1 receptor agonists, which have shown benefits in reducing HF PEF hospitalizations and cardiovascular risks. By emphasizing lifestyle changes and pharmaceutical support, their conversation underscores the importance of maintaining a healthy weight and managing related conditions to reduce the risk of heart failure. It's a comprehensive discussion aimed at empowering listeners to prioritize heart health and make informed choices.

Dr. Robert Baron outlines major updates in type 2 diabetes care, emphasizing that blood sugar control alone does not significantly reduce cardiovascular risk, though it helps prevent microvascular complications. New guidelines now prioritize medications with proven cardiovascular and kidney benefits—GLP-1 receptor agonists and SGLT2 inhibitors—over traditional first-line therapy like metformin. Baron explains how these newer drugs not only lower blood sugar but also reduce the risk of heart attack, stroke, kidney disease, and heart failure, with added benefits such as weight loss. He also covers changes in screening, diagnosis, blood pressure goals, and individualized treatment strategies based on age, comorbidities, and patient preferences. [Health and Medicine] [Show ID: 40756]

This week, we explore the potential role of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with systemic lupus erythematosus (SLE) and comorbid type 2 diabetes (T2D)—a population historically excluded from landmark SGLT2i trials. Our guest, Dr. Karen Costenbader, discusses the rationale behind the study, the nuances of trial emulation design, and key findings regarding cardiovascular and renal outcomes, infection risk, and prescribing patterns in this complex cohort. We also unpack implications for clinical decision-making and the evolving landscape of metabolic and cardiovascular care in autoimmune disease. 

In this focus issue on Heart Failure in Practice, JACC Editor-in-Chief Dr. Harlan Krumholz examines how contemporary research continues to refine and at times challenge our understanding of heart failure management. This week's episode features a first-of-its-kind trial on dual therapy with SGLT2 inhibitors and MRAs, new real-world data on heart failure with improved EF, and sobering insights into what happens when foundational therapies are withdrawn. Also explored: sex-specific risks in genetic cardiomyopathies, the limitations of standard stroke prediction tools, and the case for modernizing ICD eligibility criteria. As always, the episode concludes with a synthesized summary of key takeaways for clinicians.

Send us a textWelcome back Rounds Table Listeners! Today we have a solo episode with Dr. Mike Fralick. This week, he discusses a recently published trial exploring the simultaneous initiation of SGLT2 inhibitors and finerenone (a nonsteroidal mineralocorticoid receptor antagonist) in persons with chronic kidney disease and type 2 diabetes. Here we go!Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (0:00 – 9:28).Calling keen trainees! (9:29 - 10:28)Trainees, med students, residents: The Rounds Table and Trial Files are looking for keen individuals to support our efforts.Trial Files is a free monthly newsletter on practice-changing trials, delivered straight to your inbox (https://trialfiles.substack.com/).Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter Brian Kennedy is a renowned biologist, leader in aging research, and director of the Center for Healthy Longevity at the National University of Singapore. In this episode, Brian shares insights from ongoing human aging studies, including clinical trials of rapamycin and how dosing strategies, timing, and exercise may influence outcomes. He presents two key models of aging—one as a linear accumulation of biological decline and the other as an exponential rise in mortality risk—and explains why traditional models of aging fall short. He also explains why most current aging biomarkers lack clinical utility and describes how his team is working to develop a more actionable biological clock. Additional topics include the potential of compounds like alpha-ketoglutarate, urolithin A, and NAD boosters, along with how lifestyle interventions—such as VO2 max training, strength building, and the use of GLP-1 and SGLT2 drugs—may contribute to longer, healthier lives. We discuss: Brian's journey from the Buck Institute to Singapore, and the global evolution of aging research [2:45]; Rethinking the biology of aging: why models like the hallmarks of aging fall short [9:45]; How inflammation and mTOR signaling may play a central, causal role in aging [14:15]; The biological role of mTOR in aging, and the potential of rapamycin to slow aging and enhance immune resilience [17:30]; Aging as a linear decline in resilience overlaid with non-linear health fluctuations [22:30]; Speculating on the future of longevity: slowing biological aging through noise reduction and reprogramming [33:30]; Evaluating the role of the epigenome in aging, and the limits of methylation clocks [39:00]; Balancing the quest for immortality with the urgent need to improve late-life healthspan [43:00]; Comparing the big 4 chronic diseases: which are the most inevitable and modifiable? [47:15]; Exploring potential benefits of rapamycin: how Brian is testing this and other interventions in humans [51:45]; Testing alpha-ketoglutarate (AKG) for healthspan benefits in aging [1:01:45]; Exploring urolithin A's potential to enhance mitochondrial health, reduce frailty, and slow aging [1:05:30]; The potential of sublingual NAD for longevity, and the combination of NAD and AKG for metabolic and exercise enhancement [1:09:00]; Other interventions that may promote longevity: spermidine, 17

In this episode, CardioNerds Dr. Anna Radakrishnan and Dr. Apoorva Gangavelli are joined by prevention expert Dr. Martha Gulati and heart failure expert Dr. Anu Lala to discuss heart failure with preserved ejection fraction (HFpEF), a multifactorial, evolving challenge, particularly in women. In this episode, we delve into the distinctive clinical presentation and pathophysiology of HFpEF among women, exploring both traditional and gender-specific risk factors, from metabolic and inflammatory processes to the impact of obesity, sleep apnea, and gender-specific conditions. We also discussed the latest evidence on prevention strategies and emerging therapies that not only target HFpEF symptoms but also address underlying risk factors. This conversation highlights the importance of multidisciplinary, holistic care to advance diagnosis, management, and ultimately, patient outcomes for women with HFpEF. Audio editing by CardioNerds academy intern, Christiana Dangas.  Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls - HFpEF in Women HFpEF Is a Multisystem Syndrome:HFpEF in women involves more than just diastolic dysfunction—it represents a convergence of metabolic, inflammatory, and hormonal factors that make its diagnosis and management uniquely challenging. Visceral Adiposity Drives Risk:Obesity isn't just excess weight; central or visceral adiposity actively promotes inflammation, insulin resistance, and microvascular dysfunction, which are crucial in triggering HFpEF in women. Early Identification Is Key:Recognizing—and treating—subtle risk factors such as sleep-disordered breathing, hypertension, and subtle metabolic dysfunction early, especially in women who may underreport symptoms, can prevent progression to HFpEF. Holistic, Lifespan Approach Matters:Effective HFpEF care involves managing the whole cardiometabolic profile with tailored lifestyle interventions, advanced medications (e.g., SGLT2 inhibitors, GLP-1 agonists), and even cardiac rehabilitation, which remain critical at every stage, even after diagnosis. Tailoring Prevention to Unique Risks in Women:Gender-specific factors such as postmenopausal hormonal changes, pregnancy-related complications, and autoimmune conditions demand a customized prevention strategy, reminding us that prevention isn't one-size-fits-all. Show notes - HFpEF in Women Notes drafted by Dr. Apoorva Gangavelli 1. What are the gender-based differences in HFpEF presentation? HFpEF in women often presents with more subtle symptoms such as exertional dyspnea and fatigue, which may be mistakenly attributed to aging or obesity. Women tend to have a higher prevalence of preserved ejection fraction despite a similar heart failure symptom burden to men. The diagnostic challenge is compounded by lower natriuretic peptide levels influenced by hormonal factors, particularly postmenopausal estrogen deficiency, leading to false negatives and underdiagnosis. 2. How do traditional and gender-specific risk factors contribute to the development of HFpEF in women? Traditional risk factors include obesity, hypertension, diabetes, and metabolic syndrome. Gender-specific risk factors encompass pregnancy-related complications, menopause, and autoimmune diseases, which may uniquely affect cardiovascular structure and function in women. The interaction between visceral adiposity and systemic inflammation is central in predisposing women to HFpEF. 3. What underlying pathophysiological mechanisms make women more susceptible to HFpEF? Chronic inflammation and endothelial dysfunction contribute to myocardial stiffness and diastolic dysfunction. ...

Join us as we review recent practice-changing articles on suzetrigine for acute pain, the risk of PAD events from SGLT2 inhibitors, the safety of very low LDL, and the benefits of restrictive vs liberal transfusion strategies in acute MI with anemia. Fill your brain hole with a delicious stack of hotcakes! Featuring Rahul Ganatra (@rbganatra), Matt Watto (@doctorwatto), and special guest Molly Brett (Paul Williams got a break and took a much-needed vacation this week!). Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Credits Written and Hosted by: Rahul Ganatra MD, MPH; Molly Brett MD, and Matthew Watto MD, FACP Cover Art: Matthew Watto MD, FACP Reviewer: Leah Witt, MD Technical Production: Pod Paste Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Show Segments Intro, guest introduction, disclaimer Cognitive safety of very low LDL Cholesterol Suzetrigine for acute pain Risk for amputation associated with SGLT2 inhibitors Transfusion strategies in acute MI with anemia revisited Outro Sponsor: Freed Visit Freed.ai and usecode: CURB50 to get $50 off your first month when you subscribe.  Sponsor: Ezeresus Listeners of the Curbsiders podcast get access to a 2-month free trial, letting them use 100% of the features of the app. For more information visit www.ezresus.com/curbsiders Sponsor: Bombas  Enjoy worldwide shipping to over two hundred countries. Head over to Bombas.com/curb and use code curb for 20% off your first purchase. Sponsor: Continuing Education Company Special offer for Curbsiders listeners: Save30% on all online courses and live webcasts with promocode CURB30. Visit www.CMEmeeting.org/curbsiders to explore all offerings and claim your discount.